Morgan Stanley
BNTX icon

Morgan Stanley’s BioNTech BNTX Stock Holding History

Morgan Stanley’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.8M Buy
492,092
+9,681
+2% +$911K ﹤0.01% 2321
2026
Q1 		$42.9M Sell
482,411
-198,258
-29% -$20.4M ﹤0.01% 2258
2025
Q4 		$64.8M Buy
680,669
+77,653
+13% +$7.82M ﹤0.01% 1840
2025
Q3 		$59.5M Buy
603,016
+28,324
+5% +$3.03M ﹤0.01% 1871
2025
Q2 		$61.2M Sell
574,692
-138,914
-19% -$14M ﹤0.01% 1730
2025
Q1 		$65M Sell
713,606
-29,777
-4% -$3.33M ﹤0.01% 1580
2024
Q4 		$84.7M Buy
743,383
+67,467
+10% +$7.7M 0.01% 1380
2024
Q3 		$80.3M Sell
675,916
-471,881
-41% -$43.4M 0.01% 1410
2024
Q2 		$92.2M Buy
1,147,797
+63,887
+6% +$5.84M 0.01% 1235
2024
Q1 		$100M Buy
1,083,910
+455,659
+73% +$43.7M 0.01% 1196
2023
Q4 		$66.3M Buy
628,251
+47,541
+8% +$4.79M 0.01% 1457
2023
Q3 		$63.1M Buy
580,710
+10,482
+2% +$1.16M 0.01% 1370
2023
Q2 		$61.5M Sell
570,228
-388,280
-41% -$43.7M 0.01% 1412
2023
Q1 		$119M Buy
958,508
+509,637
+114% +$70M 0.01% 962
2022
Q4 		$67.4M Buy
448,871
+108,244
+32% +$16.7M 0.01% 1277
2022
Q3 		$45.9M Buy
340,627
+65,931
+24% +$10.1M 0.01% 1384
2022
Q2 		$41M Sell
274,696
-20,965
-7% -$3.2M 0.01% 1547
2022
Q1 		$50.4M Buy
295,661
+9,346
+3% +$1.57M 0.01% 1303
2021
Q4 		$73.8M Sell
286,315
-48,352
-14% -$13.2M 0.01% 1084
2021
Q3 		$91.4M Buy
334,667
+14,095
+4% +$4.48M 0.01% 899
2021
Q2 		$71.8M Sell
320,572
-156,225
-33% -$29.5M 0.01% 1054
2021
Q1 		$52.1M Buy
476,797
+167,626
+54% +$17.8M 0.01% 1148
2020
Q4 		$25.2M Buy
309,171
+209,835
+211% +$20.6M ﹤0.01% 1593
2020
Q3 		$6.88M Buy
99,336
+76,131
+328% +$5.46M ﹤0.01% 2393
2020
Q2 		$1.55M Buy
23,205
+9,553
+70% +$477K ﹤0.01% 3823
2020
Q1 		$798K Buy
13,652
+12,331
+933% +$480K ﹤0.01% 4107
2019
Q4 		$44K Buy
+1,321
New +$29.6K ﹤0.01% 5894

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Morgan Stanley's BNTX Position: Q2 2026 in Review

Morgan Stanley increased its BioNTech (BNTX) stake by 2% in Q2 2026, buying an estimated $911K and bringing the position to 492,092 shares worth $45.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2321.

Morgan Stanley first reported a position in BNTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $119M in Q1 2023. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Morgan Stanley held 492,092 shares of BioNTech worth $45.8M as of Q2 2026.
  • Morgan Stanley bought 9,681 BioNTech shares in Q2 2026, an estimated $911K.
  • BioNTech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2321 holding.
  • Morgan Stanley first reported a position in BioNTech in Q4 2019 and has held it in 27 quarters since.
  • Morgan Stanley's BioNTech position peaked at $119M in Q1 2023.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.